Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
REMED is a prospective, phase II, open-label, randomised controlled trial testing superiority
of dexamethasone 20 mg vs 6 mg. The trial aims to be pragmatic, i.e. designed to evaluate the
effectiveness of the intervention in conditions that are close to real-life routine clinical
practice. The study is multi-centre and will be conducted in the intensive care units (ICUs)
of ten university hospitals in the Czech Republic. This is an open-label trial in which the
participants and the study staff will be aware of the allocated intervention. Blinded
pre-planned statistical analysis will be performed.
Phase:
Phase 4
Details
Lead Sponsor:
Brno University Hospital
Collaborators:
General University Hospital in Prague Masaryk University Military University Hospital Praha St. Anne's University Hospital Brno Third Faculty of Medicine Charles University Tomáš Baťa Regional Hospital University Hospital Královské Vinohrady University Hospital Motol Prague University Hospital Olomouc University Hospital Ostrava University Hospital Plzeň Vascular surgery, University hospital Královské Vinohrady, Prague